CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Therapure Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Therapure Biopharma Inc
2585 Meadowpine Blvd
Phone: (416) 660-9830p:416 660-9830 MISSISSAUGA, ON  L5N 8H9  Canada Fax: (416) 660-9830f:416 660-9830

Business Summary
Therapure Biopharma Inc (Therapure) is a Canada-based biopharmaceutical company. The Company focuses on manufacturing biologics for its customers and the development, manufacture and sale of its own blood and plasma-related therapeutic products. Therapure is engaged in outsourced pharmaceutical development and manufacturing (CDMO) services under the banner Therapure Biomanufacturing, and product development under the banners, Therapure Biologics and Therapure Innovations (Products). Under Therapure Biologics, it seeks to enter the plasma-derived specialty drug products market with a portfolio of its own products, which it intends to manufacture using a protein separation technology called PlasmaCap EBA. Therapure has a pipeline of new drug product candidates focused in the areas of liver cancer (TBI 302), anemia (TBI 304H) and organ preservation (TBI 310). It provides manufacturing solutions to clients ranging from large pharmaceutical companies to mid-sized biotech companies.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201512/31/2014Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Secretary GabrielDe Alba 46
President, Chief Executive Officer, Director NicholasGreen 50
Chief Financial Officer David A.Long 11/18/2015 11/18/2015
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Hemosol BioPharma Inc
Therapure Biomanufacturing
Therapure Innovations

General Information
Number of Employees: 300 (As of 9/30/2015)
Outstanding Shares: 4,152,546 (As of 9/30/2015)
Fax Number: (416) 660-9830
Email Address: info@therapurebio.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023